Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cell Culture Media Market Outlook 2026-2035 - Featuring Profiles of Thermo Fisher Scientific, Merck KGaA, and Sartorius

globenewswire.com
TMO Thermo Fisher Scientific is listed as a leading company in the cell culture media market, which is projected to grow significantly. The article highlights the overall market growth drivers and trends, but does not provide specific sentiment for Thermo Fisher's performance within this segment. MRK Merck KGaA is identified as a key player in the expanding cell culture media market. The article focuses on market trends and growth drivers, not providing specific sentiment or performance details for Merck KGaA. COR Corning is listed as a participant in the cell culture media market, which is expected to grow substantially. The article outlines market trends and drivers but does not provide specific sentiment or performance analysis for Corning.

Cell Culture Media Market Outlook 2026-2035 - Featuring Profiles of Thermo Fisher Scientific, Merck KGaA, and Sartorius Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Cell Culture Media Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering.

Global Cell Culture Media Market to Reach USD 10.8 Billion by 2035, Driven by Biopharmaceutical Innovation

The global cell culture media market was valued at USD 3.9 billion in 2025 and is projected to reach USD 10.8 billion by 2035, expanding at a compound annual growth rate (CAGR) of 10.8%. Market growth is being supported by increasing biopharmaceutical production, advances in cell-based research, and rising demand for biologics, vaccines, monoclonal antibodies, gene therapies, and cell therapies.

The growing prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, continues to accelerate investment in advanced therapeutic research and development. At the same time, technological progress in serum-free and chemically defined media is improving scalability, reproducibility, product consistency, and laboratory efficiency. These benefits are encouraging biopharmaceutical manufacturers and research organizations to transition away from conventional serum-based formulations.

Regulatory requirements and the need to reduce contamination risks are also influencing purchasing and production strategies across the global cell culture media market. Manufacturers increasingly rely on defined formulations to support consistent batch quality in biologics and vaccine manufacturing. Continued commercialization of targeted therapies and personalized medicine is expected to create additional demand for specialized media optimized for specific cell lines and applications.

Serum-Free Media Segment Leads Market Revenue

The serum-free media segment generated USD 2.1 billion in revenue in 2025. The segment includes CHO media, HEK 293 media, BHK media, VERO cell media, insect cell media, immune cell media, and other specialized serum-free formulations.

Serum-free media maintain a strong market position because of their safety, regulatory compliance, reproducibility, and reduced dependence on animal-derived components. These formulations can minimize batch variability while supporting consistent cell growth and improved end-product quality. Their performance advantages are particularly important in the production of biologics, vaccines, monoclonal antibodies, and advanced therapies. Expanding cell therapy pipelines are expected to further strengthen adoption throughout the forecast period.

Biopharmaceutical Production Accounts for Significant Market Share

The biopharmaceutical production segment accounted for 30.8% of the cell culture media market in 2025. Segment growth reflects the rapid expansion of biologics manufacturing and increased development of vaccines, recombinant proteins, gene therapies, and cell therapies.

Rising chronic disease incidence and demand for targeted treatments are encouraging pharmaceutical and biotechnology companies to expand research programs and commercial production capacity. As manufacturers pursue scalable, reliable, and regulatory-compliant processes, demand for high-quality cell culture media is expected to remain strong.

North America Holds 39% of the Global Market

North America represented 39% of the global cell culture media market in 2025. The region benefits from established pharmaceutical and biotechnology industries, advanced research infrastructure, substantial life sciences investment, and supportive government initiatives.

Funding from organizations such as the National Institutes of Health, combined with growing demand for personalized therapies, is accelerating the use of specialized cell culture solutions. The United States remains a major contributor to regional growth, supported by continued investment in biopharmaceutical research, clinical development, and manufacturing capacity.

Competitive Landscape and Business Strategies

Leading companies operating in the cell culture media market include Merck, FUJIFILM Irvine Scientific, Thermo Fisher Scientific, Lonza, Sartorius, Cytiva, ACROBiosystems, Miltenyi Biotec, PromoCell, Biowest, JSBio, Shanghai Mediumbank Biotechnology, ProBio, Quacell Biotechnology, Elabscience, Cellplus Bio, Shanghai BioEngine, Eminence Scientific, Corning, Shanghai Basal Media, Sino Biological, and OPM Biosciences.

Market participants are expanding their portfolios of serum-free and chemically defined media to address evolving regulatory standards and reduce contamination risks. Research and development programs are increasingly focused on specialized formulations for biopharmaceutical production, cell therapy, and emerging research applications.

Strategic partnerships with research institutions, biotechnology companies, and biopharmaceutical manufacturers are helping suppliers strengthen distribution networks and expand their geographic reach. Companies are also investing in scalable production facilities, quality-control technologies, regulatory certifications, and process optimization to improve consistency and meet rising global demand. Collaborations with healthcare and life sciences organizations further enhance market visibility, technical capabilities, and brand credibility.

Comprehensive Market Analysis and Forecast

Key Attributes:

Key Topics Covered:

Chapter 1 Methodology and Scope

1.1 Market scope and definition

1.2 Research approach

1.3 Quality commitments

1.3.1 GMI AI policy and data integrity commitment

1.3.1.1 Source consistency protocol

1.4 Research trail and confidence scoring

1.4.1 Research trail components

1.4.2 Scoring components

1.5 Data collection

1.5.1 Partial list of primary sources

1.6 Data mining sources

1.6.1 Paid sources

1.6.1.1 Sources, by region

1.7 Base estimates and calculations

1.7.1 Revenue share analysis

1.7.2 Base year calculation

1.8 Forecast model

1.9 Research transparency addendum

1.9.1 Source attribution framework

1.9.2 Quality assurance metrics

1.9.3 Our commitment to trust

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

2.2 Key market trends

2.2.1 Regional trends

2.2.2 Product type trends

2.2.3 Application trends

2.2.4 End use trends

2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Rising incidence of chronic diseases

3.2.1.2 Advancements in cell culture and media technology

3.2.1.3 Increasing demand for serum and animal component-free media

3.2.1.4 Growing demand for regenerative medicine

3.2.2 Industry pitfalls & challenges

3.2.2.1 High cost of cell biology products

3.2.2.2 Stringent regulatory challenges

3.2.3 Market opportunities

3.2.3.1 Rising demand for advanced therapy medicinal products (ATMPs)

3.2.3.2 Rising contract manufacturing and CDMO partnerships

3.2.3.3 Technological advancements in custom media formulation

3.3 Growth potential analysis

3.4 Regulatory landscape (Driven by Primary Research)

3.4.1 North America

3.4.1.1 U.S.

3.4.1.2 Canada

3.4.2 Europe

3.4.3 Asia-Pacific

3.5 Technology and innovation landscape (Driven by Primary Research)

3.5.1 Current technologies

3.5.2 Emerging technologies

3.6 Cell culture media production analysis, 2025

3.6.1 Production capacity

3.6.2 Capacity utilization rate

3.6.3 Final/actual manufactured volume

3.6.4 Production trends

3.7 Pricing analysis, 2025 (Driven by Primary Research)

3.8 Patent landscape (Driven by Primary Research)

3.9 Gap analysis

3.10 Future market trends

3.11 Impact of AI and Gen AI on the market

3.12 Porter's analysis

3.13 PESTEL analysis

3.14 Cell culture media industry chain analysis

3.14.1 Upstream process analysis

3.14.1.1 Raw material sourcing

3.14.1.2 Formulation development

3.14.1.3 Manufacturing and quality control

3.14.1.4 Supply chain and logistics

3.14.2 Downstream segments

3.14.2.1 End user

3.14.2.2 Application

3.14.2.3 Distribution channels

3.15 Supply chain analysis

3.16 Customer profile analysis for major companies

Chapter 4 Competitive Landscape, 2025

4.1 Introduction

4.2 Company market share analysis

4.3 Company matrix analysis

4.4 Competitive analysis of major market players

4.5 Competitive positioning matrix

4.6 Key developments

4.6.1 Merger and acquisition

4.6.2 Partnership and collaboration

4.6.3 New product launches

4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, by Product Type, 2022-2035 ($ Mn)

5.1 Key trends

5.2 Serum-free media

5.2.1 CHO media

5.2.2 HEK 293 media

5.2.3 BHK media

5.2.4 VERO cell media

5.2.5 Insect cell media

5.2.6 Immune cell media

5.2.7 Other serum-free media

5.3 Specialty media

5.4 Chemically defined media

5.5 Stem cell culture media

5.6 Other product types

Chapter 6 Market Estimates and Forecast, by Application, 2022-2035 ($ Mn)

6.1 Key trends

6.2 Biopharmaceutical production

6.2.1 Monoclonal antibodies

6.2.2 Vaccine production

6.2.3 Other biopharmaceutical productions

6.3 Diagnostics

6.4 Drug screening and development

6.5 Tissue engineering and regenerative medicine

6.6 Research purpose

6.7 Other applications

Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)

7.1 Key trends

7.2 Pharmaceutical and biotechnology companies

7.3 Hospital and diagnostic laboratories

7.4 Research and academic institutes

7.5 Other end users

Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)

8.1 Key trends

8.2 North America

8.2.1 U.S.

8.2.2 Canada

8.3 Europe

8.3.1 Germany

8.3.2 UK

8.3.3 France

8.3.4 Spain

8.3.5 Italy

8.3.6 Netherlands

8.4 Asia-Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.5 Latin America

8.5.1 Brazil

8.5.2 Mexico

8.5.3 Argentina

8.6 Middle East and Africa

8.6.1 South Africa

8.6.2 Saudi Arabia

8.6.3 UAE

Chapter 9 Company Profiles

9.1 ACROBiosystems

9.2 Biowest

9.3 Cellplus Bio

9.4 Corning

9.5 Cytiva

9.6 Elabscience

9.7 Eminence Scientific

9.8 FUJIFILM Irvine Scientific

9.9 JSBio

9.10 Lonza

9.11 Shanghai Mediumbank Biotechnology

9.12 Merck

9.13 Miltenyi Biotec

9.14 OPM Biosciences

9.15 ProBio

9.16 PromoCell

9.17 Quacell Biotechnology

9.18 Sartorius

9.19 Shanghai BioEngine

9.20 Shanghai Basal Media

9.21 Sino Biological

9.22 Suzhou Womei

9.23 Thermo Fisher Scientific

For more information about this report visit https://www.researchandmarkets.com/r/pvukw

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.